IGF2BP2 and hepatocellular carcinoma: Recently, autoantibodies against the insulin-like growth factor 2 mRNA binding protein (IMP) IMP2/p62, which was originally identified as an autoantigen in a hepatocellular carcinoma patient [5], were shown to be elevated in patients with esophageal squamous carcinoma [6].